HD-OPM Archive
Hashtags

#statinslpa

6 posts

Statins raise Lp(a) 5-20% yet still cut heart attack and stroke, including with high Lp(a)

Jan 21, 2025 · Louis Nervegna ♥ 16 · 💬 22 Lp(a)

Louis cites meta-analyses showing statins can raise Lp(a) by 5-20%, and a video of Stanford's Joshua Knowles explaining this is clinically unimportant and that statins are an important part of treating genetically high Lp(a). Across 25 statin trials, lowering LDL by about 75 mg/dL cut MACE roughly 40%, with larger relative reductions in primary prevention.

Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure

Nov 10, 2026 · Louis Nervegna ♥ 9 · 💬 12 ↩ 1 Lp(a)

Louis proposes that Lp(a)HORIZON failed because aggressive statin treatment (78% on high-intensity statins) may have already neutralized oxidized phospholipids carried by Lp(a). A shared abstract (Sherratt et al., Eur Heart J) found atorvastatin's active metabolite scavenges free radicals and inhibits oxidation of Lp(a) and small dense LDL better than other statins. This is a lab-based hypothesis.

Statins cut heart attack and stroke risk in high Lp(a) despite raising it 5-20%

Jun 20, 2026 · Louis Nervegna ♥ 11 · 💬 7 Lp(a)

Louis explains that Lp(a) carries LDL cholesterol and sticks in artery walls, so lowering total LDL-C with statins cancels much of the risk from high Lp(a). Meta-analyses show statins raise Lp(a) 5-20%, but a Stanford expert argues this is clinically unimportant given the outcome benefit across 25 randomized trials.

Statins remain essential for high Lp(a) even though they raise Lp(a) 5-20%

Apr 06, 2025 · Louis Nervegna ♥ 8 · 💬 9 Lp(a)

Louis shares a video of Stanford's Joshua Knowles explaining why the small statin-related rise in Lp(a), shown in meta-analyses of RCTs, does not matter clinically and why statins are an important treatment for genetically high Lp(a). He cites over 25 long-running statin RCTs, including primary prevention trials, showing large reductions in heart attack and stroke.

Big swings in Lp(a) usually reflect acute inflammation, not an intervention working

Jun 20, 2026 · Louis Nervegna ♥ 11 · 💬 4 ↩ 1 Lp(a)

Louis explains that Lp(a) is largely genetic but behaves as an acute-phase reactant, so infection, surgery, extreme exercise, vaccine reactions or inflammatory flares can shift test results temporarily. Large changes are therefore usually due to inflammation, and blaming big jumps on statins can hide an underlying problem.

Lp(a) makes clots form more easily and resist breakdown via OxPL and apo(a)

Nov 10, 2026 · Louis Nervegna ♥ 3 Lp(a)

Louis shares a summary of an ATVB commentary by Rafael Zubiran explaining why high Lp(a) may be worse than LDL. Its oxidized phospholipids activate monocytes to make tissue factor, and apo(a) resembles plasminogen and competes with clot breakdown, producing denser, harder-to-dissolve clots. Louis notes statins, especially atorvastatin, may neutralize OxPL and aspirin lowers clotting risk.